Previous 10 | Next 10 |
Shares of the clinical-stage biotech Atea Pharmaceuticals (NASDAQ: AVIR) closed the week down by a whopping 68.6%, according to data from S&P Global Market Intelligence . The biotech's stock plummeted last Tuesday after announcing that its oral antiviral pill, known as AT-52...
Atea Pharmaceuticals posted underwhelming data from a Phase 2 trial of its COVID antiviral therapy AT-527 on Oct. 19, causing its stock price to fall by 66%. The drug failed to meet its endpoint of reduction of the SARS-Cov-2 virus compared to placebo in a subset of patients - around ...
In a session where the major averages posted ho-hum gains, Canadian cannabis stocks proved a source of excitement on Tuesday. A mention on CNBC sparked a midday rally in Tilray (NASDAQ:TLRY), which pulled much of the rest of the sector higher with it. Canopy Growth (NASDAQ:CGC), Aurora Cannab...
The Nasdaq Composite (NASDAQINDEX: ^IXIC) has been one of the most resilient stock market indexes for investors over the past 18 months. After taking a hit with the rest of the market at the beginning of the COVID-19 pandemic, the Nasdaq has bounced the most of any major benchmark. ...
Gainers: Camber Energy (NYSE:CEI) +27%. HCW Biologics (NASDAQ:HCWB) +21%. Fuel Tech (NASDAQ:FTEK) +23%. RedHill (NASDAQ:RDHL) +19%. Harmony (NASDAQ:HRMY) +15%. Ginkgo Bioworks (NYSE:DNA) +15%. Arqit Quantum (NASDAQ:ARQQ) +14%. AlloVir (NASDAQ:ALVR) +13%. ViewRay (NASDAQ:VRAY) +13%. Full Truck...
Atea Pharmaceuticals’ (NASDAQ: AVIR) Covid-19 treatment, developed in collaboration with Roche, did not meet the necessary requirement to reduce the amount of Covid-19 in non-hospitalized patients with mild to moderate disease. The company’s shares decreased 70.9% to...
Shares of Atea Pharmaceuticals (NASDAQ: AVIR) , a clinical-stage biopharmaceutical company, are falling hard after the company shared disappointing clinical-trial data. Investors are worried about what will become of AT-527, an oral COVID-19 treatment, after failing a phase 2 study....
Gainers: AlloVir (NASDAQ:ALVR) +14%, InflaRx (NASDAQ:IFRX) +14%, Harmony Biosciences (NASDAQ:HRMY) +13%, Omeros (NASDAQ:OMER) +11%, Prelude Therapeutics (NASDAQ:PRLD) +11%. Losers: Galera Therapeutics (NASDAQ:GRTX) -68%, Atea Pharmaceutic...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Energous (NASDAQ: WATT ) stock is getting a boost on Tuesday after announcing approval from the U.S. Federal Communications Commission (FCC) for its wireless power technology. Source: Michael Vi / Shutterstock.com...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Atea Pharmaceuticals (NASDAQ: AVIR ) stock is on the move Tuesday after providing an update from its Phase 2 Moonsong clinical trial update. Source: Shutterstock The Moonsong trial was evaluating the effectiv...
News, Short Squeeze, Breakout and More Instantly...
Atea Pharmaceuticals Inc. Company Name:
AVIR Stock Symbol:
NASDAQ Market:
Atea Pharmaceuticals Inc. Website:
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barr...
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 20...
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H’24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to ...